亚洲在线日韩伦理片,96精品国产AⅤ一区二区,青鸟影视网,yy黄色频道,国内精品久久久精品AV电影院

德琪（浙江）醫藥科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD

Latest News

Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform

 * The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promisin...

2025-08-22 18:14 1966

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

 SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2025-08-19 13:26 1266

Antengene Announces XPOVIO? Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

 - This approval for XPOVIO? in combination with bortezomib and dexamethasone (XVd) for the treatmen...

2025-07-28 18:49 2025

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

 SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2025-07-28 10:40 1585

Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025

 * ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KE...

2025-05-23 12:31 2499

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA? (pembrolizumab)

 - ATG-022 is?Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA? (pembrolizumab) is MSD's anti-...

2025-05-20 20:00 1803

Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality

 SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-04-26 08:30 3379

Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

 SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-04-24 10:26 2098

Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality

 SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ --?Antengene Corporation Limited ("Antengene", ...

2025-03-26 16:28 1848

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

 SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ --?Antengene Corporation Limited ("Antengene", ...

2025-03-21 19:29 4135

XPOVIO? (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

 - XPOVIO? is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 202...

2025-03-05 13:00 1943

XPOVIO? (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

 - XPOVIO? is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 202...

2025-03-05 13:00 2124

Antengene Announces XPOVIO? Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

 * XPOVIO? is the first XPO1 inhibitor approved in Taiwan for the treatment of adultpatients with ...

2025-02-13 17:30 3037

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

 SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-12-10 08:30 2278

Antengene Announces XPOVIO?'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

 SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-11-28 13:04 2599

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

 SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 09:08 2078

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

 SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 08:30 2104

Antengene Announces XPOVIO? (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

 * This approval for XPOVIO? for the treatment of patients with multiple myeloma (MM) marks the th...

2024-10-18 10:35 3581

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

 SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-10-07 13:14 2491

Antengene Announces XPOVIO? (selinexor) Approved for Commercialization in Thailand

 * XPOVIO? is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO? has been approv...

2024-09-23 17:42 4147
12345 ... 9